ClinicalTrials.gg
RecruitingNCT05268666Updated Jun 15, 2023

A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors

A Phase 1/2 interventional study of JBI-802 in Locally Advanced Solid Tumor and Metastatic Solid Tumor, sponsored by Jubilant Therapeutics Inc.. Recruiting at 4 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-15.

Sponsored by Jubilant Therapeutics Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 11 months ago, but the record still lists the study as recruiting.
  • Started Apr 2022; still recruiting 4 years 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
126
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 2,056 studies in Neoplasm Metastasis with a site in United States — 346 open to participants now, 543 under way, 58 of them phase 3. Neoplasm Metastasis · United States.

Planned enrollment
440th of 1,865
126 · median 43
Started
2022
with 105 others
Phase 1/2
268 of 2,056
64 open now
Primary completion
2024-12
later than 44 of 541 live
Registered
1,649th of 2,056
by date

Among the 2,056 studies in Neoplasm Metastasis with a site in United States, this one is the 440th largest by planned enrollment of the 1,865 interventional ones that give a count, is one of 106 that started in 2022, is one of 268 in phase 1/2, reaches primary completion later than 44 of the 541 other live ones, and was the 1,649th registered.

Neoplasm Metastasis

4,051 studies on the registry are indexed under Neoplasm Metastasis; 893 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

346 of the 2,056 studies in Neoplasm Metastasis with a site in United States are open now. Recruiting first, the newest first:

341 more — sign in →

All 346 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 693 Neoplasm Metastasis studies recruiting now, 541 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,056 studies in Neoplasm Metastasis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine the maximum-tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of JBI-802 in patients with Advanced Solid Tumors.The efficacy of the RP2D will be evaluated in phase 2 in patients with solid tumors of neuroendocrine differentiation.

Read the detailed description

This is a multi-center, first in human, open-label, 2-part, dose escalation and expansion study to define safety, tolerability, maximum tolerated dose, pharmacologically active dose, assess preliminary efficacy, and explore predictive and pharmacodynamic biomarkers in up to 126 participants with advanced solid tumors. Expansion cohorts of participants, treated at the RP2D, with small cell lung cancer (SCLC), neuroendocrine prostate cancer (NEPC), and other neuroendocrine-derived cancers will be enrolled to obtain additional safety and efficacy data. Starting dose will be 10 mg orally once daily, 4 days on and 3 days off cycle.

03

Conditions studied

  • Locally Advanced Solid Tumor
  • Metastatic Solid Tumor

Browse trials for

Keywords

  • SCLC
  • neuroendocrine prostate cancer
  • neuroendocrine
  • JBI-802
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Males or females aged ≥18 years at Screening
  • (ANC) ≥1500 cells/mm3.
  • count ≥100,000 cells/mm3.
  • Total ≤1.5×. Patients with Gilbert's syndrome may be enrolled with up to 3.0xULN.
  • and ALT ≤2.5×ULN (unless liver are present then up to 5×ULN is allowed).
  • Calculated (CrCL) ≥60 mL/min (Cockcroft-Gault formula).
  • (PT) or activated partial thromboplastin time (aPTT) ≤1.5×ULN if participant is not anticoagulated (Note: If participant is on anticoagulants, the participant must be on a stable dose for at least 2 weeks prior to study entry.
  • Must have at least one on CT scan or MRI per 1.1
  • (ECOG) performance status of ≤2
  • Other criteria may apply

Part 1:

  • Participants with a confirmed diagnosis of locally advanced or metastatic solid tumors (except microsatellite stable colorectal cancer and hepatocellular carcinoma) who have no available effective therapeutic options.

Part 2:

  • Small cell lung cancer: Participants must have a histologic diagnosis of advanced SCLC not amenable to curative therapy and have received ≤2 prior regimens, which must have included a and a platinum-based chemotherapy.
  • De novo or treatment-emergent NEPC
  • Basket of neuroendocrine-derived tumors, excluding SCLC and treatment-induced NEPC. Participants must have unresectable locally advanced or metastatic disease and have no available effective therapeutic options.

Exclusion criteria

Exclusion Criteria:

  • Known malignant central nervous system (CNS) disease other than neurologically stable, treated - defined as having no evidence of progression or hemorrhage for at least 4 weeks after treatment (including brain radiotherapy). Must be off any systemic for the treatment of symptomatic brain metastases for at least 14 days prior to enrollment.
  • Severe or unstable medical condition, such as congestive heart failure ( [NYHA] Class III or Class IV), ischemic heart disease, uncontrolled hypertension, uncontrolled diabetes mellitus, psychiatric condition, as well as an uncontrolled cardiac arrhythmia requiring medication (≥Grade 2, according to Version 5), myocardial infarction within 6 months prior to starting study treatment, or any other significant or unstable concurrent cardiac illness. Note: Stable chronic atrial fibrillation is allowed.
  • Use of strong inhibitors of within 14 days or 5 half-lives (whichever is longer) or grapefruit juice or grapefruit containing products within 7 days prior to Cycle 1 Day 1.
  • Use of strong inducers of CYP3A within 14 days or 5 half-lives (whichever is longer) prior to Cycle 1 Day 1.
  • Use of strong inhibitors of cytochrome CYP2D6 within 14 days or 5 half-lives (whichever is longer) prior to Cycle 1 Day 1.
  • Use of strong inducers of CYP2D6 within 14 days or 5 half-lives (whichever is longer) prior to Cycle 1 Day 1.
  • History of other previous or concurrent cancer that would interfere with the determination of safety or efficacy assessment
  • Surgery (eg, stomach bypass) or medical condition that might significantly affect absorption of medicines
  • Other criteria may apply
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
126 participants (estimated)

Study arms

  • Experimental
    JBI-802

    10 mg JBI-802 once daily as the starting dose with 4 days on/3 days off cycle

    Drug: JBI-802

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum-Tolerated Dose (MTD)

    Time frame: 28-day cycle

  2. Investigator-Assessed ORR (Part 2)

    Defined as either complete response (CR) or partial response (PR) as defined by RECIST version 1.1

    Time frame: Up to 30 days from the last dose of study drug

Secondary outcomes

  1. Incidence of AEs

    Characterized overall and by type, seriousness, relationship to study treatment, timing, and severity graded according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0

    Time frame: Up to 30 days from the last dose of study drug

  2. Cmax: Maximum Plasma Concentration JBI-802

    Defined as the maximum observed drug concentration observed in plasma over all PK sample concentrations.

    Time frame: Baseline up to 28 days from the last dose of study drug

  3. Tmax: Time of Maximum Plasma Concentration JBI-802

    Defined as the time at which the Cmax occurs.

    Time frame: Baseline up to 28 days from the last dose of study drug

  4. Clast: Last Observed (quantifiable) Plasma Concentration in units of ng/mL JBI-802

    Last Observed (quantifiable) Plasma Concentration in units of ng/mL JBI-802

    Time frame: Baseline up to 28 days from the last dose of study drug

  5. AUC(0-last): Area Under the Concentration-time Curve from Dosing (time 0) to Time of Last Measured Concentration JBI-802

    AUCs will be reported in units of h×ng/mL

    Time frame: Baseline up to 28 days from the last dose of study drug

  6. AUC(0-t) (partial AUC): Area Under the Concentration-time Curve from Dosing (time 0) to Time t JBI-802

    May be computed for one or more values of t, with specific values of t determined after observing the data; AUCs will be reported in units of h×ng/mL

    Time frame: Baseline up to 28 days from the last dose of study drug

  7. Vd/F: Apparent Volume of Distribution During Terminal Phase (Vz/F) After Oral Administration calculated as (CL/F)/ Ke

    Volume will be reported in units of L.

    Time frame: Baseline up to 28 days from the last dose of study drug

  8. CL/F: Apparent Oral Clearance (CL/F) computed as Dose/AUC

    Clearance will be reported in units of L/h.

    Time frame: Baseline up to 28 days from the last dose of study drug

  9. t½: The Apparent Terminal Elimination Half-life JBI-802

    The time required for the drug concentration to decrease by a factor of one-half in the terminal phase. t½ can be estimated as ln(2) / Ke. t1/2 will be reported in units of h.

    Time frame: Baseline up to 28 days from the last dose of study drug

  10. Investigator-Assessed Overall Response Rate (ORR) (Part 1)

    ORR is defined as the percentage of patients with a confirmed complete response (CR) or a partial response based on RECIST 1.1

    Time frame: Up to 30 days from the last dose of study drug

  11. Duration of Response (DOR)

    Time from the date of first documented CR or PR, assessed by the investigator and based on RECIST 1.1 to the documented date of progressive disease (PD) or death, whichever occurred first

    Time frame: Up to 30 days from the last dose of study drug

  12. PFS: Progression Free Survival

    The time from the date the patient started study drug to the date the patient experiences an event of disease progression

    Time frame: Date patient started study drug to date of progression, assessed up to 30 months

  13. OS: Overall Survival

    The time from the date patient started study drug to death for any reason

    Time frame: Date patient started study drug to date of death for any cause, assessed up to 30 months

  14. PSA 50 Response Rate in Patients with Prostate Cancer

    The percentage of patients who experience a ≥50% decline in PSA from baseline.

    Time frame: Baseline up to 30 days from the last dose of study drug

07

Study locations

1 of 4 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2022 (actual). Primary completion is estimated for Dec 2024, 32 months after the start.

Of 129 industry-sponsored phase 1/2 interventional studies under Neoplasm Metastasis, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 89. This study's planned 32 months is below that.

Counting every sponsor, half of 215 studies reached it within 62 months; a quarter within 41 and three quarters within 89.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2022
First posted
Mar 7, 2022
StartActual
Apr 8, 2022
Primary completionEst.
Dec 2024
CompletionEst.
Aug 2025
Last update
Jun 15, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05268666
Lead sponsor
Jubilant Therapeutics Inc.
Responsible party
Sponsor
First posted
Mar 7, 2022
Start date
Apr 8, 2022
Primary completion
Dec 2024 (estimated)
Completion
Aug 2025 (estimated)
Last update
Jun 15, 2023

Study contacts

Chief Scientific Officer
Contact
luca.rastelli@jubilanttx.com
(443) 515-9637
Director, Program Management
Contact
rajeev.mohan@jubilanttx.com
Program Manager
study director · Jubilant Therapeutics Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: JBI-802

Start the discussion